Loading...

Matthew Stachler, MD, PhD

Title(s)Assistant Professor, Pathology
SchoolSchool of Medicine
Address513 Parnassus Ave, HSW
San Francisco CA 94143
Phone415-514-1902
EmailMatthew.Stachler@ucsf.edu
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Clinically, I am a Molecular Pathologist focused on using advanced, cutting edge tests to drive personalized medicine in cancer diagnostics and treatment.

    My lab works to understand the process of premalignant progression to invasive cancer, specifically focusing on cancers (esophageal and gastric adenocarcinoma) and pre-malignant conditions (columnar and intestinal metaplasia or Barrett’s esophagus) of the upper gastrointestinal tract as a model system.

    As a disease that is often closely monitored and sampled, Barrett’s esophagus and esophageal adenocarcinoma provides an idea system to study the changes leading up to and driving invasive disease. Additionally, Barrett’s esophagus and esophageal adenocarcinoma are extremely important diseases to understand in their own as esophageal adenocarcinoma has one of the fastest rising incidences of any solid tumor and despite our understanding that it arises from a metaplastic field, we still do an extremely poor job of identifying patients early before advanced disease develops.

    We have taken the approach to first understand the factors important in human tissues through advanced ‘omics’ and digital imaging approaches and then use this understanding to build model systems and functional studies. It is our goal to use the knowledge and understanding gained in these studies to develop novel biomarkers, screening strategies, and treatments to identify and treat people early before advanced disease develops.

    Collapse Research 
    Collapse Research Activities and Funding
    Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
    NIH/NIDDK K08DK109209Apr 15, 2016 - Mar 31, 2021
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse Collaboration Interests
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 Jul 14. Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. PMID: 32665297.
      View in: PubMed   Mentions:    Fields:    
    2. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020 02; 52(2):219-230. Sethi NS, Kikuchi O, Duronio GN, Stachler MD, McFarland JM, Ferrer-Luna R, Zhang Y, Bao C, Bronson R, Patil D, Sanchez-Vega F, Liu JB, Sicinska E, Lazaro JB, Ligon KL, Beroukhim R, Bass AJ. PMID: 32025000.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    3. Risk stratification in Barrett's esophagus patients with diagnoses of indefinite for dysplasia: the definite silver bullet has not (yet) been found. Gastrointest Endosc. 2020 01; 91(1):11-13. Frei NF, Stachler MD, Bergman JJGHM. PMID: 31865984.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov. 2020 02; 10(2):288-305. Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, Hoadley KA, Wang TC, Church G, Wong KK, Petricoin EF, Cox AD, Lowy DR, Der CJ, Bass AJ. PMID: 31771969.
      View in: PubMed   Mentions: 4     Fields:    
    5. Colorectal Adenocarcinoma, Not Just One Disease. Cell Mol Gastroenterol Hepatol. 2019; 8(2):293-294. Stachler MD. PMID: 31129094.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors. Mod Pathol. 2019 05; 32(5):666-674. Soong TR, Nayor J, Stachler MD, Perencevich M, Jajoo K, Saltzman JR, Lindeman NI, Srivastava A. PMID: 30455417.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Biomarkers for Barrett's esophagus - a contemporary review. Expert Rev Mol Diagn. 2018 11; 18(11):939-946. Qureshi AP, Stachler MD, Haque O, Odze RD. PMID: 30345836.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut. 2019 03; 68(3):389-399. Yu M, Maden SK, Stachler M, Kaz AM, Ayers J, Guo Y, Carter KT, Willbanks A, Heinzerling TJ, O'Leary RM, Xu X, Bass A, Chandar AK, Chak A, Elliott R, Willis JE, Markowitz SD, Grady WM. PMID: 29884612.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    9. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018 07; 155(1):156-167. Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. PMID: 29608884.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    10. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol. 2018 06; 31(6):989-996. Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, Lauwers GY, Odze RD, Srivastava A. PMID: 29422640.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. PMID: 28978556.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    12. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017 01 06; 8:13897. Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ. PMID: 28059068.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    13. PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations. Appl Immunohistochem Mol Morphol. 2016 May-Jun; 24(5):313-9. Stachler MD, Rinehart EM, Garcia E, Lindeman NI. PMID: 26067136.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Sep; 47(9):1047-55. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. PMID: 26192918.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    15. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1123-1129. Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. PMID: 26081225.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    16. Filter Paper-based Nucleic Acid Storage in High-throughput Solid Tumor Genotyping. Appl Immunohistochem Mol Morphol. 2015 May-Jun; 23(5):389-96. Stachler M, Jia Y, Sharaf N, Wade J, Longtine J, Garcia E, Sholl LM. PMID: 25221956.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015 Jun; 44(2):473-89. Kaz AM, Grady WM, Stachler MD, Bass AJ. PMID: 26021206.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    18. Novel molecular insights from routine genotyping of colorectal carcinomas. Hum Pathol. 2015 Apr; 46(4):507-13. Stachler MD, Rinehart E, Lindeman N, Odze R, Srivastava A. PMID: 25683705.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    19. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014; 9(10):e109440. Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ. PMID: 25350844.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    20. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. PMID: 25165165.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCellsCTClinical Trials
    21. Critical role for IL-1ß in DNA damage-induced mucositis. Proc Natl Acad Sci U S A. 2014 Feb 11; 111(6):E702-11. Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, Shaul YD, Stachler M, Voronov E, Apte RN, Pagano M, Pikarsky E, Karin M, Ghosh S, Ben-Neriah Y. PMID: 24469832.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    22. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013 Dec 12; 39(6):1095-107. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, Lencer WI, Jobin C, Blumberg RS. PMID: 24290911.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    23. Case report: Calcifying fibrous tumor presenting as an asymptomatic pelvic mass. Indian J Radiol Imaging. 2011 Oct; 21(4):306-8. Giardino AA, Ramaiya NH, Shinagare AB, Jagannathan JP, Stachler MD, Raut CP. PMID: 22223947.
      View in: PubMed   Mentions:
    24. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol Ther. 2008 Aug; 16(8):1467-73. Stachler MD, Chen I, Ting AY, Bartlett JS. PMID: 18560418.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    25. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 2006 Jun; 13(11):926-31. Stachler MD, Bartlett JS. PMID: 16482202.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    26. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 2006 Jul; 14(1):97-106. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. PMID: 16624620.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    Matthew's Networks
    Concepts (185)
    Derived automatically from this person's publications.
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _